Eli Lilly’s Fast-Acting Insulin Lispro Receives CHMP’s Positive Opinion in Patients with Diabetes

 Eli Lilly’s Fast-Acting Insulin Lispro Receives CHMP’s Positive Opinion in Patients with Diabetes

Eli Lilly’s Fast Acting Insulin Lispro Receives CHMP’s Positive Opinion in Patients with Diabetes

Shots:

  • The approval is based on two studies, PRONTO-T1D & PRONTO-T2D assessing fast-acting insulin lispro (URLi) vs Humalog both in combination with insulin glargine/ degludec in 1,222 & 673 patients with T1D & T2D respectively
  • The PRONTO-T1D & PRONTO-T2D resulted in meeting 1EPs of non-inferior A1C reduction @26wks., reduction in blood glucose spikes at both one and two hrs. following a test meal
  • The fast-acting formulation of insulin lispro, currently being evaluated in adults with T1D & T2D. If approved, it will be commercialized under the trade name Liumjev in the EU

Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: StraitTimes

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post